Health

    Pandemics & Infectious Diseases

    Zoonose & Vector Borne Diseases

Post-Doctoral Fellowships

Portugal

2013.11.30

Long non-coding RNA control infectivity and transmission of Trypanosoma brucei parasites

A treatment that killed 10% of patients would certainly be considered unacceptable by modern medical standards. And yet, that is the best that doctors can currently offer victims of sleeping sickness. This disease, which strikes rural Africa, in particular, is caused by a parasite called trypanosome. It is passed to a human or animal by the bite of a tsetse fly, much like mosquitoes may transmit the parasite causing malaria. Once in a person’s blood, it travels to the brain where it interrupts the usual sleep/wake cycles. Victims are neither fully conscious nor fully asleep and, without today’s very aggressive drugs, the patient will die.
Fabien Guegan believes the parasite’s complex life cycle holds the key to halting sleeping sickness. Between the tsetse fly’s stomach and a person’s blood, trypanosome inhabits two very different environments. Yet, very quickly, it is able to adapt, changing its shape and metabolism by activating different genes. Dr. Guegan is hot on the trail of the molecules he thinks may act as orchestra conductors, synchronizing the many different elements of this transformation. Disrupting the “conductor” could make the whole trypanosome symphony fall apart. His strategy of targeting the transmission process inside the parasite could make it possible to block the spread between infected humans and animals and more tsetse flies. If so, this could mean a huge step forward in controlling sleeping sickness.

Disrupting the Sleeping Sickness Symphony

When Sleeping Becomes Fatal

Sleeping sickness is a fatal disease caused by trypanosome, a parasite transmitted by the tsetse fly. Dr. Fabien Guegan is studying how trypanosomes survive in the human blood using an ingenious strategy to evade the immune system called antigenic variation. He is also studying how this parasite adapts to extreme environmental changes, passing from human blood to the tsetse fly midgut. Understanding the adaptive strategies used by trypanosome will provide new avenues for developing treatments.

To add or modify information on this page, please contact us at the following address: community.research@axa.com

Fabien
GUEGAN

Institution

Instituto de Medicina Molecular

Country

Portugal

Nationality

French

ORCID Open Researcher and Contributor ID, a unique and persistent identifier to researchers

Related articles

Health

Medical Treatment & Drug Development

Pandemics & Infectious Diseases

Antimicrobials, Antibiotics & Drug Resistances

Bacteria & Other Microorganisms

Drug Delivery

Mécénat des Mutuelle

France

New Molecule to Combat Antibiotic-Resistant Childhood Sepsis

The global spread of antibiotic resistance requires the identification of new bacterial drug targets, the design and synthesis of innovative... Read more

Nalini
RAMA RAO

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Health

Pandemics & Infectious Diseases

Climate Change

Healthcare Systems

Zoonose & Vector Borne Diseases

Climate Adaptation & Resilience

Global Warming

Public Health & Health Policy

AXA Project

United Kingdom

New Observatory on Dengue Outbreaks

Vector-borne diseases – human illnesses caused by parasites, viruses and bacteria transmitted by living organisms such as mosquitoes, ticks, and... Read more

Oliver
BRADY

London School of Hygiene & Tropical Medicine

Health

Pandemics & Infectious Diseases

Terrestrial Biodiversity

Climate Change

Zoonose & Vector Borne Diseases

Wildlife & Invasive Species

AXA Award

Switzerland

Grand Jet d'Or Award on Planetary Health

The Covid-19 pandemic has highlighted our fragility as societies in the face of zoonoses, diseases that appear in the animal... Read more

Geneva Health Forum
(GHF)

Geneva Health Forum